We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to make a dramatic difference in patients’ lives.
THE THIRD ROCK TEAM
Our team has a proven record of translating disruptive technologies into valuable business enterprises. Working closely with leading scientific and business visionaries as well as industry partners, we identify opportunities to change the future of medicine and rigorously vet those ideas through our discovery process to develop the vision, strategy and plan needed to succeed.
A FORMULA FOR INNOVATION
We only invest in the best of those ideas. We are actively involved in the early stages of our companies’ development, typically serving as members of the founding management teams, to build a strong foundation, put in place the right people and culture, and set the companies on a path to scientific and operational excellence.
We believe in the companies we launch and make big initial investments, often complemented by strategic alliances, to enable our companies to advance life-changing therapies, devices and diagnostics. By creating value for patients, we create value for our investors.
Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri...
ARTBIO, a Cambridge, MA-based clinical-stage radiopharmaceutical company, raised $132M in Series B funding.
The round was led by Sofinnova Investments and B Capital, along with an existing investor and participation from F-Prime, Omega Fund...
Corvia Medical, a company dedicated to transforming the treatment of heart failure, announced the closing of a $55 million funding round from its existing investment syndicate, which includes Third Rock Ventures, General Catalyst Partners, ...
In a significant move for heart failure treatment, Corvia Medical, Inc. has successfully closed a $55 million funding round. This funding comes from a group of existing investors, including Third Rock Ventures, General Catalyst Partners, Ac...
Corvia Medical, Inc, a Tewksbury, MA-based company dedicated to improve the treatment of heart failure, raised $55M in funding.
Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two investors.
T...
Existing investors provide funding to finish international RESPONDER-HF trial
TEWKSBURY, Mass., June 17, 2025 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the succe...
Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con...
Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, launched today w...
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
By ReutersJanuary 7, 202511:00 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The Nasdaq logo is displayed at the Nasdaq Mark...
Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial
TEWKSBURY, Mass., Dec. 21, 2024 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it ...
Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is...
Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease...
Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ...
In the realm of biopharmaceuticals, a new player has emerged, armed with ambition and a hefty $101 million in Series A funding. Trace Neuroscience is on a mission to reshape the landscape of genomic medicine, particularly for those grapplin...
Trace Neuroscience – a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases – announced its launch with a $101 million Series A funding led by Third Rock Ventures, with partic...
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt
TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transfo...
Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a...
Cancer immunotherapy comes in several forms, and one area of growing research interest is a type of drug called a T cell engager. These drugs bind to a cancer cell and a T cell simultaneously, bringing both of them together to spark a thera...
This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
It was just about three weeks ago that the layoffs started to feel constant. Every day, more and ...
Third Rock Ventures just closed out a massive $1.1 billion fund, bringing its total raised over the last 15 years to an eye-popping $3.8 billion—and the firm has no plans to slow down.
“We believe in a mentality of Third Rock forever,” part...
Good morning! Below are some of the top tech startup news for today, Thursday, June 6, 2019.
Apple is reportedly looking to buy robotaxi start-up Drive.ai. Apple is reportedly in talk to buy acquired a new and struggling autonomous vehicle...
Third Rock Ventures, LLC, a Boston, MA-based life sciences venture capital firm, closed Third Rock Ventures V, LP, at $770m.
With Fund V, the firm will continue to execute on its strategy of discovering, launching and building innovative li...
Good morning! Here are some of the top tech startup news stories for today, Thursday, August 9.
Revolution Precrafted, the ‘Ikea of homes’ startup, could be the next billion-dollar startup from the Philippines. Revolution Precrafted, a Phi...
To enable the machine learning, we will use high-quality data that has already been collected, but we will also invest heavily in the creation of our own datasets using high throughput experimental approaches, datasets that are designed exp...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casma Therapeutics, Inc., a biotechnology company harnessing the natural cellular process of autophagy to design powerful new medicines, launched today with $58.5 million in Series A funding from Third Roc...
Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Roc...
Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Roc...
Rheos Medicines, Inc., a Cambridge, Mass.-based is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease, raised $60m in Series A financing.
The round was led by Third Rock ...
On any bustling city street, in the middle of the afternoon, it’s probably the case that half or more people are wearing earbuds, while the rest are abiding the noise pollution all around them. No one thinks twice about it, either.
The real...
Monday: Rolling the pitch
PAREXEL, 7:30AM. A short night after landing at Logan airport, the participants went to PAREXEL in a school bus. The day started with a presentation by CEO Josef H. von Rickenbach. PAREXEL actually started as a sta...
venture leaders Life Science 2017: Walk the investors’ talk 20.06.2017 10:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
From June 12 to 16, ten Swiss startups in Life Science rocked the Boston business and innovation hub...
Tango Therapeutics, a Cambridge, MA-based new cancer therapeutics company, raised $55m in Series A funding.
Third Rock Ventures was the founding backer of the new company.
Led by Barbara Weber, M.D., interim Chief Executive Officer and a Ve...
BOSTON--(BUSINESS WIRE)--Third Rock Ventures, LLC today announced that Sarah Larson has joined as partner and chief human resources officer. In this new role, she is responsible for human resources at the firm. Sarah will also provide guida...
Healthcare venture capital firm Third Rock Ventures has added Sarah Larson as partner and chief human resources officer.
In the new role, Larson is responsible for human resources at the firm. She will also provide guidance and counsel to t...
“It’s noise pollution,” said David Lucchino, president and CEO at Frequency, said in a phone interview. “There was a great study about people who were born and spent their lives on Easter Island and people who left. The people who stayed ha...
In a company news release, Jason Gardner, CEO, president, and co-founder of Magenta Therapeutics said a new wave of stem cell science was ready for commercialization.
“Technical and scientific hurdles have relegated stem cell transplantatio...
Third Rock Ventures, LLC, a Boston, MA-based healthcare venture capital firm, closed fund IV, at $616m.
With Third Rock Ventures IV, LP, the firm will continue to execute on its strategy of creating innovative healthcare companies.
Since la...
Fund IV has not yet begun investing, according to a company representative, but the firm has established a strong track record with its first three funds. In less than 10 years, Third Rock has invested in 40 companies, advancing 40 clinical...
Another Day, Another Megamerger
At this pace the Fortune 500 will be down to around 20 companies by the end of the year. CenturyLink has agreed to acquire Level3 Communications in a deal valued at $34 billion in cash and stock, including de...
That abiding philosophy hasn’t yet found anything interesting in the consumer wearable arena to consider supporting. And so not surprisingly, consumer wearables as a group is rather conspicuous by its absence from GV’s portfolio.
By contras...
Molecular-level movies may not spark the imagination of too many directors. But for oncology patients, the imaging techniques Relay is working on represent another front in the effort to crack the code of cancer.
The technique that Relay, b...
It’s long been the case that life sciences investors don’t get the attention that their more traditional tech counterparts do. They’re underrepresented on lists of top investors in venture capital. They’re also remarkably underfunded, accor...
Pliant Therapeutics, Inc., a newly formed Redwood City, California-based company that aims to discover and develop new therapies to treat the pathologic process of fibrotic disorders, raised $45m in Series A financing.
The round was led by ...
Boston, MA-based healthcare venture capital firm Third Rock Ventures, LLC, has added Michael W. Bonney as a partner.
Mr. Bonney, who most recently served as chief executive officer of Cubist Pharmaceuticals Inc. (a subsidiary of Merck &...
Quip secured $30M; OpenGov raised $25M; Niantic landed $20M
OpenGov, which allows local governments to bring their data to the cloud, has an additional $25 million, it announced on Thursday The oversubscribed funding round included existing...
Decibel Therapeutics, a Cambridge, Mass.-based newly formed hearing company focused on discovering and developing new medicines to protect, repair and restore hearing, is being launched with a $52m Series A financing.
The round was led by T...
Indeed, Third Rock companies generally take this broad scale approach to their respective fields – take Bluebird Bio’s approach to gene therapy, or Constellation Pharmaceuticals’ approach to epigenetics.
Starr, a cofounder at Third Rock, sa...
General Assembly raised $70M; Neon Therapeutics secured $55M; Dolly landed $8M
Social Finance (SoFi for short), a lending startup has raised a monster round of funding, taking $1 billion from SoftBank, with existing Third Point Ventures and...
Investors in the company include Google Ventures, Khosla Ventures and Bill Gates
We like to complain about the world a lot, but this really is such a cool time to be alive. We are coming up with amazing technology at a more rapid pace than ...
Revolution Medicines, Inc., a Redwood City, CA-based newly formed developer of new therapies derived from natural products, raised $45m Series A financing.
Third Rock Ventures, LLC, participated in the foundation and the funding of the comp...
REDWOOD CITY, CA, Third Rock Ventures today announced the formation of REVOLUTION Medicines, Inc. with a $45 million Series A financing.
>> Click here for more funding data on REVOLUTION Medicines
>> To export REVOLUTION Med...
The technology comes from chemist Martin Burke at the University of Illinois, who has formulated just-right reaction conditions to make this work. This process was published in Nature a year ago, showing how many drug structures can be buil...
Constellation Pharmaceuticals also announced it has begun two additional Phase 1 clinical studies of its lead drug, CPI-0610. One trial focuses on patients with multiple myeloma, and the other studies the drug in patients with acute leukemi...
Nurix, Inc., a San Francisco, California-based company that discovers and develops therapies that modulate the ubiquitin proteasome system (UPS), raised $25.1m in Series B financing.
Backers included Third Rock Ventures and The Column Group...
PanOptica, a Bernardsville, NJ-based biopharmaceutical company focused on ophthalmology therapies, closed up to $45m in Series B funding.
The round was led by Novo Ventures and Third Rock Ventures with participation from SV Life Sciences.
T...
Voyager Therapeutics, a Cambridge, Mass.-based newly formed gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), launched with $45m in Series A financing.
Third Ro...
In three days, 15 startups emerged, aimed at changing an industry that daily impacts every single individual.
"What you guys are doing are transforming healthcare and changing lives," said Andrea Ippolito, co-leader of MIT Hacking...
Blueprint Medicines, a Cambridge, MA-based oncology company, completed a $25m Series B financing.
The round was led by Nextech Invest Ltd., with participation from founding investors Third Rock Ventures and Fidelity Biosciences as well as p...
Editas Medicine, a Cambridge, MA-based genome editing company, secured a $43m Series A financing.
The round was led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Founded by ...
Third Rock Ventures, one of the premiere healthcare venture capital firms, is loaded for bear again.
The Boston-based VC group recently closed its 3rd fund, a $516 million tranche that will go towards launching some 15 to16 new life science...
With surgery, it’s important to take a hands-on approach. The same applies to investing. Third Rock Ventures announced the close of its third fund this morning, $516 million dedicated solely to health care startups.
Third Rock Ventures is a...
Third Rock Ventures, LLC, a Boston, MA-based venture capital firm focused on backing healthcare companies, held the final close of Fund III, at $516m.
Fund III will continue to launch and build up to 16 healthcare companies, with a particul...
We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
With surgery, it’s important to take a hands-on a...
Since its inception in 2007, the firm has raised about $1.3 billion and funded or launched 31 companies, including cancer immunotherapy company Jounce Therapeutics earlier this year. Last year, it spearheaded Global Blood Therapeutics, a dr...
Jounce Therapeutics, Inc., a Cambridge, MA-based newly formed company focused on the discovery and development of cancer immunotherapies, raised $47m in Series A financing from Third Rock Ventures.
Led by Cary Pfeffer, M.D., interim CEO, Ro...
The funding will help build Jounce’s product engine to develop biologics with a broad spectrum of targets, according to a company statement. It will utilize tumor immunobiology and antibody discovery.
Third Rock Ventures Partner Dr. Cary Pf...
Cibiem, a New York City-based medical device startup, has raised $10m in Series A financing.
Backers include SV Life Sciences and Third Rock Ventures.
Co-founded by CTO Mark Gelfand and President Howard R. Levin, M.D., Cibiem leverages its ...
MyoKardia, Inc., a San Francisco, CA-based newly formed company that is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease, has raised $38m in Series A financin...
Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ...
Among the company’s founders are three scientific researchers from University of California, San Francisco: Dr. Matthew Jacobson, Dr. Andrej Sali and Dr. Jack Taunton, and two Third Rock directors: Dr. Charles Homcy and Craig Muir. Dr. Mark...
Global Blood Therapeutics, Inc., a San Francisco, CA-based newly formed product-focused company building a pipeline of oral for the treatment of chronic blood-based diseases and genetic disorders, has raised $40.7m in Series A financing fro...
Blueprint Medicines, a Cambridge, MA-based developer of personalized cancer therapies, announced Fidelity Biosciences as a new investor.
Fidelity Biosciences has joined existing founding investor Third Rock Ventures in the company’s previou...
But the investments and the board seats don’t necessarily mean the fund stands ready to fill GSK and J&J drug pipelines. If either pharma wants to license a compound financed by the fund, the companies will have to join the mix of pharm...
But just as important, the agreement provides an exit for Warp Drive’s investors. The partnership is structured in a way that allows Third Rock to force Sanofi to buy the company if certain performance criteria are met, Viehbacher explained...
The cancer drug made the cover of Time magazine in 2001 around the time it was first approved by the FDA to treat patients with advanced Philadelphia chromosome positive chronic myeloid leukemia, a blood and bone marrow disease linked to a ...
Warp Drive Bio, a Boston, MA-based newly formed company that is developing proprietary genomic search engine and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signatur...
Ember Therapeutics, a Boston, MA-based newly formed company focused on leveraging recent findings in the area of brown fat to develop a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes ...
Agios Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, has secured $78m in Series C financing.
Backers include three new large p...
Allena Pharmaceuticals, Inc., a Newton, Mass.-based company developing and commercializing innovative non-systemic oral protein therapeutics, has secured $15m in Series A venture capital financing.
Backers include Bessemer Venture Partners,...
SAGE Therapeutics, a Boston, MA-based newly formed company that focuses on building central nervous system (CNS) products, has raised $35m in Series A funding from Third Rock Ventures.
Founded by Steven Paul, M.D., the former executive vice...
TOPICA Pharmaceuticals, Inc., a Palo Alto, CA-based clinical research stage pharmaceutical company, has raised $27m in a Series B funding.
Backers include Third Rock Ventures and existing investors Prospect Venture Partners and Yasuda Enter...
Foundation Medicine, Inc., a Cambridge, MA-based cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine care, has closed an expanded Series A financing, bringing the total amount raised in the round to...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Catching up on an eventful week in Boston- and San Francisco-area venture capital personnel moves…
—Bijan Sabet of Spark Capital and Fred Wilson of Union Square Ventures are l...
Lotus Tissue Repair, a Cambridge, MA-based developer of recombinant collagen type VII (rC7) technology as a treatment for dermatologic conditions, closed a $26m Series A financing.
The round was led by Third Rock Ventures.
The company inten...
Boston investment firm Third Rock Ventures LLC has raised $426 million for its second (oversubscribed) fund and is opening a San Francisco office to continue its practice of "launching and supporting transformative life sciences compan...
Founded in 2007 with a $378 million fund, Third Rock has invested in 15 life sciences companies, including Constellation Pharmaceuticals (gene-repair therapies), Agios Pharmaceuticals (cancer metabolism) and Zafgen (obesity therapies). The ...
Third Rock Ventures, L.L.C, a Boston, MA-based venture capital firm focused on building life sciences companies, has held the final closing of Fund II, raising $426m.
Third Rock has also announced changes and additions to its team, which in...
Foundation Medicine, Inc., a Boston, MA-based personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, has completed a $25m Series A financing.
The round was led by Third Rock ...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Constellation Pharmaceuticals, a new drug-discovery company based in Cambridge, MA, today announced that it has raised $32 million in Series A financing.
One of the lead inves...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Third Rock Ventures, the new Boston venture firm zeroed in on funding early stage, local life sciences companies, announced the hiring of three new partners yesterday. The com...
Featured companies: Accenx, Chlorogen, Third Rock Ventures
Ex-Millennium execs found new life-sciences venture fund, raise $378M — Several former executives of Millennium Pharmaceuticals have founded a new Boston-based venture firm called T...
Two top-tier biotech venture firms have collaborated for the first time to create, incubate, and lead a series A financing round for Magenta Therapeutics.
Third Rock Ventures and Atlas Venture summoned a total of $48.5 million for the new C...
Right on the heels of embarking on two new Phase 1 trials, epigenetics player Constellation Pharma has raised $5 million in an internal round from existing investors – a solid chunk of change.
“It’s just the amount we needed to top off our ...
A former Stanford University researcher who served as chief computing officer at Alphabet anti-aging business Calico Labs has launched a startup of her own. In a Medium blog post, Daphne Koller offered an overview of her new business, insit...
Nature’s been a fantastically bountiful source of medicine, sure. But turns out the drug compounds found secreted by a sea sponge or on the underside of a log have very elaborate chemical structures. When used for unintended purposes like, ...
